Find out what’s happening at Micreos

Learn more about our current news, views and updates
For any media enquiries please contact Natalie Samuel: contact@micreos.com

View All
  • New publication introducing MEndoB: A revolutionary precision antimicrobial against Staphylococcal infections.

    The unique design of MEndoB makes this an invaluable Precision Antimicrobial for combatting staphylococci, including antimicrobial resistant strains such as methicillin-resistant S. aureus (MRSA). MEndoB could address a wide range of conditions where staphylococcal species have caused an imbalance or disruption to the normal microbial community in or on the human body

    Read More
  • Micreos Logo

    Ground-breaking data published in Blood

    Today, the University of Copenhagen shared the positive results of an investigational study, published in Blood providing ground-breaking evidence that Staphylococcus aureus and its toxins induce drug resistance in malignant T-cells against therapeutics such as HDAC inhibitors and chemotherapies commonly used for cutaneous T cell lymphoma (CTCL). Importantly, the study shows that bacterial killing by Micreos engineered, S. aureus-targeting endolysin countered this drug-resistance effect.

    Read More
  • Investigational study provides evidence that recombinant endolysin XZ.700* is a promising novel non-antibiotic treatment strategy aimed at controlling Staphylococcus aureus (S. aureus) colonization of lesional skin in Cutaneous T-cell lymphoma (CTCL).

    Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression.

    Read More
  • Micreos Logo

    Micreos spins off to focus on innovative pharmaceuticals to transform patient care in the treatment of chronic and acute bacterial infections.

    Since its founding in 2005, Micreos has become a world leading developer of endolysin and phage technology, enabling the targeted killing of only unwanted bacteria while protecting the rest of the Microbiome.

    Read More
  • Micreos Logo

    Micreos’ Alternative to Antibiotics Secures Next €25 Million

    Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.

    Read More
  • Micreos ramps up the global fight against antimicrobial resistance and builds world-class antimicrobial vector engineering team.

    Dr. Matthew Dunne, Dr. Samuel Kilcher and Dr. Anja Keller join us from the Swiss Federal Institute of Technology (ETH Zurich), with the goal of developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.

    Read More
  • Micreos Pharmaceuticals announces success of its XZ.700 technology in selectively eliminating Staphylococcus aureus pathogen without triggering resistance

    Zug, Switzerland, 14 April 2022 — Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in selectively targeting and killing the harmful Staphylococcus aureus bacterial pathogen while maintaining a healthy microbiome and preventing antimicrobial resistance (AMR).

    Read More
  • Micreos Pharmaceuticals welcomes Trine Ahlgreen and Carsten Edwards to its Executive team to accelerate its next phase of development

    Zug, Switzerland, 5-April 2022 — Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer.

    Read More
  • Micreos Logo

    Micreos appoints Matt Regan as CEO of its Pharmaceutical business

    The Hague, October 14, 2021 - Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland.

    Read More
  • Micreos Logo

    Micreos secures €32 million for its endolysin-based platform as sustainable alternative to antibiotics

    THE HAGUE, The Netherlands, 30 September, 2021  - Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria.

    Read More